Third-Party Risk Management Services (TPRM)

Nymox

Nymox focuses on developing therapies for prostate health issues.

About

Nymox is a pharmaceutical corporation engaged in the research and development of treatments for conditions related to prostate health, particularly Benign Prostate Hyperplasia (BPH). The company is working on a novel injectable therapy designed to selectively target prostate gland cells. Their ongoing research includes studies on Fexapotide, which aims to provide safe and effective treatment options for men suffering from an enlarged prostate.

Resources & Links

Related Categories